HGAL 通过结合多种细胞骨架蛋白抑制淋巴瘤播散
研究利用新型动物模型在体内证实 HGAL 降低淋巴瘤播散并延长生存,并通过无偏蛋白质组学发现 HGAL 可与多种细胞骨架蛋白相互作用,包括微管蛋白,从而影响细胞运动。
要点
- HGAL 高表达是 DLBCL 和经典霍奇金淋巴瘤生存期延长的预测因素。
- HGAL 在体内抑制淋巴瘤播散并延长生存。
- HGAL 与微管蛋白等多种细胞骨架蛋白相互作用,可能调控细胞运动。
核心结论
- HGAL 在体内抑制淋巴瘤播散并延长生存,其作用可能与结合多种细胞骨架蛋白调控细胞运动有关。
研究设计与样本
- 研究采用新型动物模型进行体内 DLBCL 播散实验,并使用无偏蛋白质组学方法分析 HGAL 相互作用蛋白。
主要发现
- HGAL 降低淋巴瘤播散并延长生存。
- HGAL 可与多种细胞骨架蛋白相互作用,包括微管蛋白。
- HGAL 与微管蛋白的相互作用可能参与其对细胞运动的影响。
临床怎么用
- HGAL 表达状态可能有助于预测 DLBCL 和经典霍奇金淋巴瘤患者的生存预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human germinal center-associated lymphoma (HGAL) is an adaptor protein specifically expressed in germinal center lymphocytes. High expression of HGAL is a predictor of prolonged survival of diffuse large B-cell lymphoma (DLBCL) and classic Hodgkin lymphoma. Furthermore, HGAL expression is associated with early-stage DLBCL, thus potentially limiting lymphoma dissemination. In our previous studies, we demonstrated that HGAL regulates B-cell receptor signaling and cell motility in vitro and deciphered some molecular mechanisms underlying these effects. By using novel animal models for in vivo DLBCL dispersion, we demonstrate here that HGAL decreases lymphoma dissemination and prolongs survival. Furthermore, by using an unbiased proteomic approach, we demonstrate that HGAL may interact with multiple cytoskeletal proteins thereby implicating a multiplicity of effects in regulating lymphoma motility and spread. Specifically, we show that HGAL interacts with tubulin, and this interaction may also contribute to HGAL effects on cell motility. These findings recapitulate previous observations in humans, establish the role of HGAL in dissemination of lymphoma in vivo, and explain improved survival of patients with HGAL-expressing lymphomas.
引用
- Jiang X, Lu X, Gentles AJ, et al. HGAL inhibits lymphoma dissemination by interacting with multiple cytoskeletal proteins. Blood Adv. 2021. PMID: 34543391. doi:10.1182/bloodadvances.2021004304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。